Thomas Graney has served on the Notable Board of Directors since 2023. He has extensive global finance experience that spans corporate development, commercial strategy, portfolio management and supply chain management, communication and investor relations.
Graney served as the chief executive officer of Oxurion NV from May 2021 to December 2023. Prior to his promotion to CEO, Graney served as the chief financial officer of Oxurion NV from October 2020. From February 2019 to April 2020, he served as the chief financial officer of Generation Bio. Prior to that, Graney was chief financial officer of Vertex Pharmaceuticals Inc. from September 2017 to February 2019 and the chief financial officer and senior vice president of corporate strategy at Ironwood Pharmaceuticals from September 2014 to September 2017. Prior to Ironwood Pharmaceuticals, he spent more than 20 years working with Johnson & Johnson and its affiliates, serving for four years as worldwide chief financial officer of Ethicon. Graney currently serves as a board member and chair of the audit committee of Mogrify Ltd. and was a board member at AC Immune SA from 2017 to 2023; he is a Chartered Financial Analyst charter holder.
Graney earned a bachelor of science degree in accounting from the University of Delaware, Newark, Del. and his master of business administration degree in marketing, finance and international business from the Leonard N. Stern School of Business at New York University, New York, N.Y.
